07/08/2026
Every so often, something happens that reminds you why you never stop hoping.
The announcement that the VESSEL Project has been awarded up to $25.8 million in ARPA-H funding isn’t the end of our journey and a guaranteed treatment/cure, but it is a powerful reminder that the future for children with MSMDS is changing.
When Hailie was diagnosed, there were so many unanswered questions and so few people who even knew what MSMDS was. Today, there are world-class researchers dedicating their lives to understanding this disease and working towards treatments that once felt impossible.
We are incredibly grateful to Dr. Patty Musolino and her outstanding team at Massachusetts General Hospital. Their dedication, compassion, and determination have given so many families something priceless-hope. They continue to push the boundaries of science because they believe our children deserve better.
That every hospital visit, every research appointment, every blood sample, every family who has shared their story and every person who has supported this community has helped build the foundation for moments like this..
Research is a journey and every breakthrough takes time.This funding means the work can move forward faster. It means more opportunities to answer the questions we’ve been waiting so long to ask. And it means that, now more than ever, a treatment for MSMDS is possible.
Today, my heart is full of hope, because the path ahead has never looked more promising💜🩵
https://www.massgeneralbrigham.org/en/about/newsroom/press-releases/mgb-researchers-awarded-arpa-h-grant-to-treat-rare-genetic-vascular-diseases
Massachusetts General Hospital has been awarded an Advanced Research Projects Agency for Health (ARPA-H) contract to develop advanced personalized genomic medicines to treat rare genetic vascular diseases.